Efung Capital Dynamics | ProteLight Pharma’s World’s First Granulin-Class Antimicrobial Peptide Drug

Date： 2026-06-22

ProteLight Pharma announced that its independently developed China’s first Class 1 innovative granulin-class antimicrobial peptide drug, Puyike® (Peleganan Spray), received approval for market launch from the National Medical Products Administration (NMPA) on June 17, 2026. The drug is primarily indicated for the treatment of secondary wound infections such as burns and scalds.

Peleganan Spray is a First-in-class (FIC) new drug independently developed based on ProteLight Pharma’s Antimicrobial Peptide Drug Design Platform (AMPDDP). The successful approval marks the global debut of the first granulin-class anti-infective therapeutic.

The approval of Peleganan Spray for treating secondary wound infections including burns and scalds is supported by data from multiple pivotal clinical studies.

Efung Capital participated in ProteLight Pharma’s financing round in 2025. Looking ahead, Efung Capital will leverage its professional investment expertise and ecosystem empowerment capabilities in the biopharmaceutical sector to continue supporting ProteLight Pharma’s growth, actively facilitating the global development and commercialization of the company’s antimicrobial peptide innovative drug pipeline, and helping China-originated innovative drugs reach the world stage, bringing more Chinese solutions to the global anti-infective therapeutics landscape.

END

Previous:NoNext：Efung Dynamics | Continuously Doubling D

Related News / Recommended news More

Efung Capital CEO Zhu Pai Attends BIOCHINA 2026: Discussing the New Ecosystem of LP-GP Collaboration

2026 - 03 - 24

In March, Suzhou is gradually embracing the vitality of spring, much like China's biomedical industry, which is gathering momentum amidst transformation. On March 13, during the 11th BioChina Summit (BIOCHINA 2026), Mr. Zhu Pai, CEO of Efung Capital, was invited to attend the core session—the Global Investment Forum—where he engaged in in-depth discussions with industry peers on the theme &quo...

Frontier Biotechnologies Enters Exclusive License Agreement with GSK for siRNA Pipeline Products

2026 - 03 - 25

Frontier Biotechnologies Inc. (“Frontier Biotechnologies” or the “Company”) recently entered into an exclusive licensing agreement with global biopharmaceutical company GlaxoSmithKline (“GSK”). Under the agreement, GSK will obtain exclusive worldwide rights for the development, manufacturing, and commercialization of two siRNA pipeline assets. One candidate drug has reached the Investigational New...

Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio News

2026 - 03 - 06

Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio NewsOn March 5, 2026, the Phase IV clinical study of Oryzogen's recombinant human albumin (rice-derived) Orumin®, evaluating its "safety and efficacy in patients with hypoalbuminemia and/or hypovolemia requiring emergency treatment," achieved its first patient enrollment and completed the init...

Viestar’s Confocal Microscopy Products Selected as Outstanding Domestic Medical Equipment

2026 - 03 - 05

The year 2026 marks the beginning of the 15th Five-Year Plan period. Recently, the 11th batch of the “Outstanding Domestic Medical Equipment Product Catalogue” was officially released. Viestar’s independently developed BIOPSEE® Confocal Laser Endomicroscope and BIOPSEE® Ultra-Thin Probe-based Confocal Laser Endomicroscope were prominently selected. This recognition makes JWS Medical the ...